lenabasum   Click here for help

GtoPdb Ligand ID: 9772

Synonyms: ajulemic acid | CPL-7075 | CPL7075 | CT-3 | IP-751 | IP751
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Lenabasum (ajulemic acid) is a synthetic derivative of the non-psychoactive cannabinoid THC metabolite 11-nor-9-Carboxy-THC (PubChem CID 108207) [10]. It is a non-selective cannabinoid receptor agonist [5,7]. Lenabasum exhibits potentially useful analgesic and anti-inflammatory actions [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 66.76
Molecular weight 400.26
XLogP 6.96
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCCCCCC(c1cc(O)c2c(c1)OC(C1C2CC(=CC1)C(=O)O)(C)C)(C)C
Isomeric SMILES CCCCCCC(c1cc(O)c2c(c1)OC([C@H]1[C@H]2CC(=CC1)C(=O)O)(C)C)(C)C
InChI InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
Immunopharmacology Comments
Ajulemic acid is being investigated as a potential treatment for chronic inflammation [2]. It has been shown to attenuate the inflammatory response in murine collagen-induced arthritis and rat adjuvant arthritis models [1,9].
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Phase 2 clinical candidate for SLE- see NCT03093402
Systemic scleroderma Disease Ontology: DOID:418
OMIM: 181750
Orphanet: ORPHA90291
A Phase 3 multicenter trial to evaluate AJA's safety and efficacy in SSc has recently been initiated- see NCT03398837